Novo Nordisk A/S - Reduction of the share capital

Print
| Source: Novo Nordisk A/S
multilang-release

Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. 

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.

The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
 

Investors:
   
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren
Anders Mikkelsen
Kasper Veje (US)
+45 3079 8519
+45 3079 4461
+1 609 235 8567
haoe@novonordisk.com
armk@novonordisk.com
kpvj@novonordisk.com

Company announcement No 29 / 2017 

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/c31b86db-3096-4334-a42e-8dcbc1c5406e